A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection

[1] Crew KD(2006)Epidemiology of gastric cancer World J Gastroenterol 12 354-362

[2] Neugut AI(2006)Gastric cancer: global pattern of the disease and an overview of environmental risk factors Best Pract Res Clin Gastroenterol 20 633-649

[3] Forman D(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[4] Burley VJ(2005)An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach Int J Radiat Oncol Biol Phys 63 1279-1285

[5] Jemal A(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[6] Bray F(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[7] Center MM(2010)Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 303 1729-1737

[8] Ferlay J(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[9] Ward E(2012)Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection J Clin Oncol 30 2327-2333

[10] Forman D(2006)Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques Br J Radiol 79 497-503

[1] Crew KD(2006)Epidemiology of gastric cancer World J Gastroenterol 12 354-362

[2] Neugut AI(2006)Gastric cancer: global pattern of the disease and an overview of environmental risk factors Best Pract Res Clin Gastroenterol 20 633-649

[3] Forman D(2011)Global cancer statistics CA Cancer J Clin 61 69-90

[4] Burley VJ(2005)An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach Int J Radiat Oncol Biol Phys 63 1279-1285

[5] Jemal A(2001)Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 725-730

[6] Bray F(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 11-20

[7] Center MM(2010)Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis JAMA 303 1729-1737

[8] Ferlay J(2007)Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810-1820

[9] Ward E(2012)Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection J Clin Oncol 30 2327-2333

[10] Forman D(2006)Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques Br J Radiol 79 497-503